Yanis Boumber

Abstract Novel preclinical models that better mimic the in vivo tumor microenvironment are essential to advance understanding of tumor biology and resistance/response to therapy. Herein, we report development of a novel ex vivo patient-derived three-dimensional lung tumor model (3D-LTM) for use in evaluating response to therapy.

June 15, 2021 2 min read Save Perspective from Source/Disclosures Published by: Source: Uppaluri R, et al. Abstract 6008. Presented at: Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021. Disclosures: Merck supported the study. Uppaluri reports consultant/advisory roles with and research funding from Merck. Please see the abstract for all other researchers’ relevant financial disclosures.

CHICAGO — Updated phase 3 data from the ARCHER 1050 trial showed that dacomitinib improved OS compared with gefitinib among patients with newly diagnosed, advanced EGFR-positive non-small cell lung cancer. The findings build on previous data that demonstrate dacomitinib (PF-00299804, Pfizer) significantly prolonged PFS vs. gefitinib (Iressa, AstraZeneca). According to final results presented at ASCO, dacomitinib prolonged OS by 7.3 months and PFS by 5.5 months.